Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vanta BioscienceBOM:540729 52 PB Ratio is 0.66 as of Aug. 17, 2026, which is 73% below its 10-year median of 2.49. GuruFocus rates BOM:540729 with a GF Score™ of 52/100 and a GF Value™ of ₹11.79 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 193 Medical Diagnostics & Research companies, Vanta Bioscience ranks better than 89.12% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-17), Vanta Bioscience's share price is ₹19.64. Vanta Bioscience's Book Value per Share for the quarter that ended in Mar. 2026 was ₹29.77. Hence, Vanta Bioscience's PB Ratio of today is 0.66.
The historical rank and industry rank for Vanta Bioscience's PB Ratio or its related term are showing as below:
BOM:540729'
s PB Ratio Range Over the Past 10 Years
Min: 0.51 Med: 2.49 Max: 5.53
Current: 0.66
During the past 10 years, Vanta Bioscience's highest PB Ratio was 5.53. The lowest was 0.51. And the median was 2.49.
BOM:540729's PB Ratio is ranked better than 89.12% of 193
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.23
vs BOM:540729: 0.66
During the past 12 months, Vanta Bioscience's average Book Value Per Share Growth Rate was 80.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 2.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -10.40% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Vanta Bioscience was 51.30% per year. The lowest was -24.30% per year. And the median was 2.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vanta Bioscience PB Ratio Related Terms
Vanta Bioscience PB Ratio Historical Data
* Premium members only.
The historical data trend for Vanta Bioscience's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Vanta Bioscience's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanta Bioscience PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vanta Bioscience's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vanta Bioscience (BOM:540729) has a PB Ratio of 0.66 as of Aug. 17, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vanta Bioscience and its competitors. This is 73% below median its historical median of 2.49. Over the past decade, Vanta Bioscience's PB Ratio has ranged from 0.51 to 5.53. According to the industry distribution chart, Vanta Bioscience ranks #21 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 10.9%.
Is Vanta Bioscience's PB Ratio too high?
Vanta Bioscience's current PB Ratio of 0.66 is 73% below median its 10-year median of 2.49. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 5.53. The Medical Diagnostics & Research industry median PB Ratio is 2.23. Vanta Bioscience's value of 0.66 is 70.4% below this industry median. Based on the distribution chart, Vanta Bioscience ranks #21 out of 193 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Vanta Bioscience has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vanta Bioscience ranks #21 out of 193 companies for PB Ratio. This places Vanta Bioscience in the top 11% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.23. Vanta Bioscience's value of 0.66 is 70.4% below this benchmark. Historically, Vanta Bioscience's own PB Ratio has ranged from 0.51 to 5.53 over the past decade. While the company's 10-year median is 2.49 vs. the industry median of 2.23, Vanta Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.23, based on 193 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vanta Bioscience's current PB Ratio of 0.66 is 70.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vanta Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vanta Bioscience's current PB Ratio is 0.66, which is 73% below median its own 10-year median of 2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.79, compared to a current price of ₹19.64 — trading 66.6% above its estimated fair value. The current PB Ratio is 0.66, which is 73% below median its 10-year median of 2.49 and 70.4% below the Medical Diagnostics & Research industry median of 2.23. Vanta Bioscience's overall GF Score™ is 52/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current PB Ratio is 0.66 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanta Bioscience (BOM:540729) Overvalued in 2026?
Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued.
The current stock price of ₹19.64 is trading 66.6% above its estimated GF Value™ of ₹11.79.
GuruFocus considers Vanta Bioscience to be Significantly Overvalued.
Key valuation signals for BOM:540729:
PB Ratio: 0.66 (73% below median its 10-year median of 2.49)
GF Value™: ₹11.79 vs. price of ₹19.64 (66.6% above fair value)
Industry Position: 70.4% below the Medical Diagnostics & Research median (#21 of 193)
No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
52GF Score
Get the complete analysis for BOM:540729
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540729 has been successfully added to your 
